HOME

Company

Science

Media

Investors

Careers

Contact

中
Home
Investors
IR Announcements
Jan 01, 2022
GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the completion of $75 million (~500 million RMB) series C financing. This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital
Jan 27, 2021
GenFleet Therapeutics Completes Series B+ Financing

January 27, 2021 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology, today announced the completion of its Series B+ financing worth hundreds of millions in RMB.
Mar 08, 2020
GenFleet Therapeutics Announces Series B Financing to Boost First-in-class Drug Development

March 8, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology, announced to have completed its series B financing led by CDH Investments and Shenzhen Capital Group.

Nov 30, 2018
GenFleet Therapeutics Closes Series A Financing to Advance Clinical Development of Small Molecules for Immuno-Oncology Therapeutics

November 30, 2018 (Shanghai, China) -- GenFleet Therapeutics recently announced the close of its series A financing worth 120 million yuan, which was led by Ally Bridge Group and participated by Sinopharm Capital and CSPC Pharma.